Company news
Vivosim Labs, Inc. (NASDAQ:VIVS) news
Every Vivosim Labs, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 1, 2026
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Inst...
July 16, 2026
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
July 15, 2026
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
June 29, 2026
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal ...
April 28, 2026
VivoSim Announces Pricing of up to a $4 Million Public Offering
April 1, 2026
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
March 24, 2026
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
March 3, 2026
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in Sa...
February 11, 2026
NIO Inc. Announces Profit Alert for the Fourth Quarter of 2025
February 5, 2026
NIO Inc. Provides January 2026 Delivery Update
February 1, 2026
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
January 29, 2026
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
January 6, 2026
NIO Inc. Provides November 2025 Delivery Update
December 1, 2025
NIO Inc. Provides September and Third Quarter 2025 Delivery Update
October 1, 2025
NIO Inc. Announces Pricing of US$1 Billion Equity Offering
September 10, 2025
NIO Inc. Announces Proposed Equity Offering
September 10, 2025
NIO Inc. Achieved 31,305 Vehicle Deliveries in August 2025
September 1, 2025
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
August 14, 2025
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
May 13, 2025
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
May 7, 2025
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
April 24, 2025
VivoSim to Carry Forward Organovo 3D Bioprinting
April 23, 2025
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
April 2, 2025
Organovo Provides Business Update
March 27, 2025
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
March 25, 2025
Organovo Announces Reverse Stock Split
March 19, 2025
Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
March 6, 2025
Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
February 25, 2025
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer
January 6, 2025
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
November 20, 2024
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Associ...
November 13, 2024
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 ...
July 16, 2024
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib fo...
May 21, 2024
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
May 14, 2024
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
May 8, 2024
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction ...
April 15, 2024
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s ...
January 25, 2024
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 9, 2024
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 6, 2023
Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 8, 2023
Organovo to Participate in the H.C. Wainwright Global Investment Conference
September 8, 2023
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
November 15, 2022
Organovo Announces Postponement of Annual Meeting of Stockholders
September 6, 2022
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022
Organovo Achieves 3D Tissue Model for Crohn’s Disease
May 17, 2022
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
March 1, 2022
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
February 23, 2022